

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Please note: this is a brief report of an analysis ongoing phase 3 and 2/3 trials and not a report of a clinical trial. Relevant information where applicable is provided in the text, online protocols and cited references/links to previous publications providing details for complying with consort guidelines as indicated.

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	Not applicable
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
Introduction			
Background and	2a	Scientific background and explanation of rationale	3-4
objectives	2b	Specific objectives or hypotheses	4
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	8, protocols
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	8, protocols
Participants	4a	Eligibility criteria for participants	8, protocols
	4b	Settings and locations where the data were collected	8, protocols
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	8, protocols
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8, protocols
	6b	Any changes to trial outcomes after the trial commenced, with reasons	8, protocols
Sample size	7a	How sample size was determined	8, Table S1, proto
-	7b	When applicable, explanation of any interim analyses and stopping guidelines	8, protocols
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	8, protocols
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8, protocols
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	
concealment mechanism		describing any steps taken to conceal the sequence until interventions were assigned	8, protocols

CONSORT 2010 checklist

10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to	8, protocols
11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8, protocols
11b	-	8-9, protocols
12a		8-9, protocols
12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	9, protocols
13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Not applicable
13b	For each group, losses and exclusions after randomisation, together with reasons	Not applicable
14a	Dates defining the periods of recruitment and follow-up	https://www.ncbi.
		nlm.nih.gov/pub med/33378609 10.1056/ NEJMoa2113017
14b	Why the trial ended or was stopped	TEOMORE 1 100 17
		protocols
15	A table showing baseline demographic and clinical characteristics for each group	Table S1, Supplement
16	For each group, number of participants (denominator) included in each analysis and whether the analysis was	8-9, Table S1
	by original assigned groups	Supplement
17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Figure 1
17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Not applicable
18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Not applicable https://www.ncbi_nlm.nih.gov/pub
19	• •	med/33378609 10.1056/
		NEJMoa2113017
20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	4
		4
22		4
23	Registration number and name of trial registry	8
24	Where the full trial protocol can be accessed, if available	8
	11a 11b 12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20 21 22 23	interventions If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome To each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

CONSORT 2010 checklist Page 2

5

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

CONSORT 2010 checklist Page 3